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Because corticosteroid associated osteoporosis is often associated with increased bone turnover, the effect of intermittent intravenous infusions of pamidronate on this condition has been investigated. Methods Seventeen patients (five male) with chronic corticosteroid dependent lung disease (15 asthma, two sarcoidosis) were treated with infusions of 30 mg pamidronate once every three months for one year. These patients had been taking an average of 14 (range 7-5-40) mg prednisolone a day for an average of 14 (range 3-30) years. Bone density measurements, by dual energy x ray absorptiometry, and radiography of the dorsolumbar spine were carried out before and one year after treatment. Bone formation was assessed by measurement of serum alkaline phosphatase and bone resorption by measurement of the fasting urinary hydroxyproline : creatinine ratio at the same time as densitometry and radiography were performed. Results Pretreatment density of L2-4 and the neck of the femur was significantly lower in these patients compared with a cohort of 100 age and sex matched controls (L2-4 (mean (SEM)): 0-906 (0 050) g/ cm2 v 1-142 (0-016) glcm2; neck of femur: 0 793 (0 030) glcm2 v 0-936 (0-013)) glcm2.
After treatment there was a significant fall in serum alkaline phosphatase activity from (mean (SEM)) 220 (16) UII to 174 (9) U/l (normal 80-280 Ul1) and in the fasting urinary hydroxyproline:creatinine ratio from (mean (SEM) 0-040 (0-006) to 0-024 (0-003) (normal <0-033). A significant rise was noted in L2-4 density to 0-927 (0 047) g/ cm2; mean rise of 3-4%) . No given as an intravenous infusion in 500 ml isotonic saline over four hours once every three months. The first infusion was given when they were inpatients for noting side effects. At the time of review each patient had received five infusions (a total of 150 mg pamidronate). An assessment of each patient's dietary calcium intake was made before treatment. In five patients this was considered likely to be less than 1000 mg a day and in each case one sandocal 400 tablet twice daily was prescribed; otherwise no formal calcium supplementation was given. year of treatment by dual energy x ray absorptiometry (DEXA; Lunar DPX). In our laboratory this has a precision, in normal subjects, of 0-9% (L2-4) and 1-05% (neck of the femur). These are similar to the results obtained by others. ' 2%; fig 1) . After treatment density of the neck of the femur was 0-748 (0-025) g/cm2, which represents a mean change of 1-8% (95% CI -2-0% to 2-3%; fig 2) . In three instances L2-4 density decreased over the year of treatment and in one case no change was noted. In each of these instances bone densities before treatment were comparatively normal and were all greater than 1-000 g/cm2. Those Concentrations of parathyroid hormone, 25 (OH) D3, and 1,25 (OH) 2D3 before treatment were generally within the reference range-four patients had high parathyroid hormone values (5-8, 9-0, 8-3, 6-3 pmol/l); none had subnormal 1,25 (OH) 2D3 concentrations. The mean (SEM) hydroxyproline:creatinine ratio before treatment was increased at 0-040 (0-006), indicative of increased bone resorption. Serum alkaline phosphatase activity was within the reference range. There was a significant fall in both serum alkaline phosphatase activity (fig 3) with treatment from a mean (SEM) of 220 (16) U/I to 174 (9) U/I (p < 0-002) and in the hydroxyproline creatinine ratio from 0-040 (0 006) to 0-024 (0-003) (p < 0 01; fig 4) . No significant correlation was evident either before or after treatment between alkaline phosphatase and the hydroxyproline:creatinine ratio.
Five patients developed pyrexia (range 37-5°C-38-8°C) after treatment, which was symptomatic in four instances. This started about 24 hours after the infusion finished, lasted 12-18 hours and resolved spontaneously. This side effect is well recognised after treatment with intravenous pamidronate'8 and only occurred after the first infusion. No change was noted in peak expiratory flow rate after infusion.
Discussion
On the basis of their bone densities and the presence of fractures before treatment these patients had appreciable osteoporosis. Treatment with intravenous pamidronate seemed effective in both reducing bone turnover and increasing bone density in patients with asthma and sarcoidosis treated with supraphysiological doses of corticosteroids. Although data presented by Gennari'9 suggested that bone loss with corticosteroids occurs only in the first six months of treatment, it is likely that bone loss continues with both age and continued treatment with corticosteroids.5 This view is supported by our data, which show an increased hydroxyproline: creatinine ratio (and therefore increased bone resorption) before treatment. Therefore, although this was an open, uncontrolled study, it is likely that the increased bone density and decreased bone turnover observed are of relevance.
We have previously shown that intermittent infusions of pamidronate are effective in the treatment of Paget's disease of bone.20 Although the dose of pamidronate administered in our present study was less than that for the treatment of Paget's disease, bone turnover in corticosteroid associated osteoporosis is increased to a lesser extent than in Paget's Although increases in bone density are important, the main end point in studies of this kind must be fracture rates. The fact that new fractures have continued to occur is not surprising as the bone density, although increased, is still probably below the fracture threshold. Obviously, in the absence of a control group, it is not possible to be certain of the relevance of these further fractures. Certainly in the studies of Storm et al" and Watts et al'2 no significant change in vertebral fracture rate was seen until at least 12 months into the study. This would also seem to be the case with pamidronate treatment. Further studies with larger numbers of patients and longer term follow up are required.
The mean hydroxyproline:creatinine ratio before treatment was high, implying increased rates of bone resorption. After treatment bone resorption was reduced and bone formation also seemed to be reduced although bone density increased. A possible explanation for this paradoxical effect is that resorption is inhibited and there is then a delay before local coupling mechanisms result in a decrease in bone formation and, therefore, bone formation goes on unopposed for some weeks. 26 Several studies have suggested that vitamin D concentrations are low in corticosteroid associated osteoporosis.227 This was not the case in our study; in agreement with Hahn et al28 1,25 (OH) 2D3 concentrations were normal or high. Similarly biochemical secondary hyperparathyroidism was found in only four of our patients, a lower number than might be expected. 4 These results imply that the most important mechanism in the pathogenesis of this condition is the direct effect of corticosteroids on bone formation and resorption.
In summary, it seems that intermittent intravenous infusions of pamidronate are effective at reducing the increased bone turnover of corticosteroid associated osteoporosis. Furthermore this regimen can significantly increase bone density, which ultimately should lead to a decrease in the rate of fractures. Also this regimen seems to be well tolerated and acceptable to both the patients and the attending physicians. Long term controlled studies with this treatment are now indicated.
